- In November 2024, Nevro Corp. announced CE Mark certification in Europe for its HFX iQ spinal cord stimulation (SCS) system, enabling its marketing across countries recognizing this certification. This approval expands Nevro’s market reach and strengthens its presence in the European chronic pain management market
- In October 2024, Nevro Corp. announced new data in the Journal of Pain Research showing that its 10 kHz high-frequency spinal cord stimulation (SCS) therapy provides significant and lasting pain relief, along with clinically meaningful reductions in HbA1c and weight in patients with painful diabetic neuropathy (PDN) and Type 2 diabetes. This breakthrough strengthens Nevro’s position in the chronic pain management market and enhances its reputation for innovative solutions
